ID

31873

Beschrijving

A Study to Evaluate Ocrelizumab in Combination With Methotrexate Compared With Infliximab Plus Methotrexate in Patients With Active Rheumatoid Arthritis Currently Responding Inadequately to Etanercept or Adalimumab; ODM derived from: https://clinicaltrials.gov/show/NCT00808210

Link

https://clinicaltrials.gov/show/NCT00808210

Trefwoorden

Versies (1)
  1. 05-10-18 05-10-18 -
Houder van rechten

See clinicaltrials.gov

Geüploaded op

5 oktober 2018

DOI

Voor een aanvraag inloggen.

Licentie

Creative Commons BY 4.0
Model Commentaren :

Hier kunt u commentaar leveren op het model. U kunt de tekstballonnen bij de itemgroepen en items gebruiken om er specifiek commentaar op te geven.

Terug naar het model Commentaren
Itemgroep Commentaren voor :

Item Commentaren voor :

U moet ingelogd zijn om formulieren te downloaden. AUB inloggen of schrijf u gratis in.

Eligibility Rheumatoid Arthritis NCT00808210

Engels

Eligibility Rheumatoid Arthritis NCT00808210

1 Formulieren  
Inclusion Criteria
Beschrijving

Inclusion Criteria

Alias
UMLS CUI
C1512693
age >= 18 years
Beschrijving

Age

Datatype

boolean

Alias
UMLS CUI [1]
C0001779
current treatment for ra on an outpatient basis
Beschrijving

Therapeutic procedure Rheumatoid Arthritis | Outpatients

Datatype

boolean

Alias
UMLS CUI [1,1]
C0087111
UMLS CUI [1,2]
C0003873
UMLS CUI [2]
C0029921
active disease
Beschrijving

Active disease

Datatype

boolean

Alias
UMLS CUI [1]
C2707252
currently receiving 50 mg etanercept subcutaneously (sc) every week or 40 mg adalimumab sc every other week.
Beschrijving

Etanercept Subcutaneous U/week | Adalimumab Subcutaneous U/week

Datatype

boolean

Alias
UMLS CUI [1,1]
C0717758
UMLS CUI [1,2]
C1522438
UMLS CUI [1,3]
C0560588
UMLS CUI [2,1]
C1122087
UMLS CUI [2,2]
C1522438
UMLS CUI [2,3]
C0560588
considered by investigator to be a primary non-responder to their first anti-tnfî±
Beschrijving

Therapy non-responder Primary | Anti-tumor necrosis factor alpha drug First

Datatype

boolean

Alias
UMLS CUI [1,1]
C0919875
UMLS CUI [1,2]
C0205225
UMLS CUI [2,1]
C1562242
UMLS CUI [2,2]
C0205435
treatment for efficacy reasons
Beschrijving

Therapeutic procedure Efficacy Related

Datatype

boolean

Alias
UMLS CUI [1,1]
C0087111
UMLS CUI [1,2]
C1280519
UMLS CUI [1,3]
C0439849
Exclusion Criteria
Beschrijving

Exclusion Criteria

Alias
UMLS CUI
C0680251
rheumatic autoimmune disease other than ra, or significant systemic involvement secondary to ra
Beschrijving

Autoimmune Disease Rheumatic | Exception Rheumatoid Arthritis | Rheumatoid arthritis with systemic involvement

Datatype

boolean

Alias
UMLS CUI [1,1]
C0004364
UMLS CUI [1,2]
C0035435
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0003873
UMLS CUI [3]
C0494896
history of, or current, inflammatory joint disease other than ra (e.g., gout, reactive arthritis, psoriatic arthritis, seronegative spondyloarthropathy, lyme disease) or other systemic autoimmune disorder (e.g., systemic lupus erythematosus, inflammatory bowel disease, scleroderma, inflammatory myopathy, mixed connective tissue disease or other overlap syndrome)
Beschrijving

Inflammatory joint disease | Exception Rheumatoid Arthritis | Gout | Arthritis, Reactive | Arthritis, Psoriatic | Spondylarthropathy Seronegative | Lyme Disease | Systemic Autoimmune disease | Lupus Erythematosus, Systemic | Inflammatory Bowel Diseases | Scleroderma | Myositis | Mixed Connective Tissue Disease | Overlap syndrome

Datatype

boolean

Alias
UMLS CUI [1]
C0683381
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0003873
UMLS CUI [3]
C0018099
UMLS CUI [4]
C0085435
UMLS CUI [5]
C0003872
UMLS CUI [6,1]
C0949691
UMLS CUI [6,2]
C0521144
UMLS CUI [7]
C0024198
UMLS CUI [8]
C2895206
UMLS CUI [9]
C0024141
UMLS CUI [10]
C0021390
UMLS CUI [11]
C0011644
UMLS CUI [12]
C0027121
UMLS CUI [13]
C0026272
UMLS CUI [14]
C0410000
previous treatment with a any biologic therapy for ra (including investigational products with the exception of etanercept or adalimumab
Beschrijving

Biological treatment Rheumatoid Arthritis | Investigational New Drugs | Exception Etanercept | Exception Adalimumab

Datatype

boolean

Alias
UMLS CUI [1,1]
C1531518
UMLS CUI [1,2]
C0003873
UMLS CUI [2]
C0013230
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0717758
UMLS CUI [4,1]
C1705847
UMLS CUI [4,2]
C1122087
treatment with more than one prior anti-tnfî± therapy
Beschrijving

Anti-TNF-alpha therapy Quantity

Datatype

boolean

Alias
UMLS CUI [1,1]
C0281481
UMLS CUI [1,2]
C1265611
Terug naar het begin van de pagina

Similar models

Eligibility Rheumatoid Arthritis NCT00808210

1 Formulieren
Name
Type
Description | Question | Decode (Coded Value)
Datatype
Alias
Item Group
C1512693 (UMLS CUI)
Age
Item
age >= 18 years
boolean
C0001779 (UMLS CUI [1])
Therapeutic procedure Rheumatoid Arthritis | Outpatients
Item
current treatment for ra on an outpatient basis
boolean
C0087111 (UMLS CUI [1,1])
C0003873 (UMLS CUI [1,2])
C0029921 (UMLS CUI [2])
Active disease
Item
active disease
boolean
C2707252 (UMLS CUI [1])
Etanercept Subcutaneous U/week | Adalimumab Subcutaneous U/week
Item
currently receiving 50 mg etanercept subcutaneously (sc) every week or 40 mg adalimumab sc every other week.
boolean
C0717758 (UMLS CUI [1,1])
C1522438 (UMLS CUI [1,2])
C0560588 (UMLS CUI [1,3])
C1122087 (UMLS CUI [2,1])
C1522438 (UMLS CUI [2,2])
C0560588 (UMLS CUI [2,3])
Therapy non-responder Primary | Anti-tumor necrosis factor alpha drug First
Item
considered by investigator to be a primary non-responder to their first anti-tnfî±
boolean
C0919875 (UMLS CUI [1,1])
C0205225 (UMLS CUI [1,2])
C1562242 (UMLS CUI [2,1])
C0205435 (UMLS CUI [2,2])
Therapeutic procedure Efficacy Related
Item
treatment for efficacy reasons
boolean
C0087111 (UMLS CUI [1,1])
C1280519 (UMLS CUI [1,2])
C0439849 (UMLS CUI [1,3])
Item Group
C0680251 (UMLS CUI)
Autoimmune Disease Rheumatic | Exception Rheumatoid Arthritis | Rheumatoid arthritis with systemic involvement
Item
rheumatic autoimmune disease other than ra, or significant systemic involvement secondary to ra
boolean
C0004364 (UMLS CUI [1,1])
C0035435 (UMLS CUI [1,2])
C1705847 (UMLS CUI [2,1])
C0003873 (UMLS CUI [2,2])
C0494896 (UMLS CUI [3])
Inflammatory joint disease | Exception Rheumatoid Arthritis | Gout | Arthritis, Reactive | Arthritis, Psoriatic | Spondylarthropathy Seronegative | Lyme Disease | Systemic Autoimmune disease | Lupus Erythematosus, Systemic | Inflammatory Bowel Diseases | Scleroderma | Myositis | Mixed Connective Tissue Disease | Overlap syndrome
Item
history of, or current, inflammatory joint disease other than ra (e.g., gout, reactive arthritis, psoriatic arthritis, seronegative spondyloarthropathy, lyme disease) or other systemic autoimmune disorder (e.g., systemic lupus erythematosus, inflammatory bowel disease, scleroderma, inflammatory myopathy, mixed connective tissue disease or other overlap syndrome)
boolean
C0683381 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0003873 (UMLS CUI [2,2])
C0018099 (UMLS CUI [3])
C0085435 (UMLS CUI [4])
C0003872 (UMLS CUI [5])
C0949691 (UMLS CUI [6,1])
C0521144 (UMLS CUI [6,2])
C0024198 (UMLS CUI [7])
C2895206 (UMLS CUI [8])
C0024141 (UMLS CUI [9])
C0021390 (UMLS CUI [10])
C0011644 (UMLS CUI [11])
C0027121 (UMLS CUI [12])
C0026272 (UMLS CUI [13])
C0410000 (UMLS CUI [14])
Biological treatment Rheumatoid Arthritis | Investigational New Drugs | Exception Etanercept | Exception Adalimumab
Item
previous treatment with a any biologic therapy for ra (including investigational products with the exception of etanercept or adalimumab
boolean
C1531518 (UMLS CUI [1,1])
C0003873 (UMLS CUI [1,2])
C0013230 (UMLS CUI [2])
C1705847 (UMLS CUI [3,1])
C0717758 (UMLS CUI [3,2])
C1705847 (UMLS CUI [4,1])
C1122087 (UMLS CUI [4,2])
Anti-TNF-alpha therapy Quantity
Item
treatment with more than one prior anti-tnfî± therapy
boolean
C0281481 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
Terug naar het begin van de pagina 

Contact

Gebruik dit formulier voor feedback, vragen en verbeteringsvoorstellen.

Velden gemarkeerd met een * zijn verplicht.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial